Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 86

1.

Quantitative susceptibility mapping differentiates between blood depositions and calcifications in patients with glioblastoma.

Deistung A, Schweser F, Wiestler B, Abello M, Roethke M, Sahm F, Wick W, Nagel AM, Heiland S, Schlemmer HP, Bendszus M, Reichenbach JR, Radbruch A.

PLoS One. 2013;8(3):e57924. doi: 10.1371/journal.pone.0057924. Epub 2013 Mar 21.

PMID:
23555565
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Bevacizumab-induced tumor calcifications as a surrogate marker of outcome in patients with glioblastoma.

Bähr O, Hattingen E, Rieger J, Steinbach JP.

Neuro Oncol. 2011 Sep;13(9):1020-9. doi: 10.1093/neuonc/nor099. Epub 2011 Jul 31.

PMID:
21807668
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Differentiation of glioblastoma and primary CNS lymphomas using susceptibility weighted imaging.

Radbruch A, Wiestler B, Kramp L, Lutz K, Bäumer P, Weiler M, Roethke M, Sahm F, Schlemmer HP, Wick W, Heiland S, Bendszus M.

Eur J Radiol. 2013 Mar;82(3):552-6. doi: 10.1016/j.ejrad.2012.11.002. Epub 2012 Dec 10.

PMID:
23238364
[PubMed - indexed for MEDLINE]
4.

Benefits of contrast-enhanced SWI in patients with glioblastoma multiforme.

Fahrendorf D, Schwindt W, Wölfer J, Jeibmann A, Kooijman H, Kugel H, Grauer O, Heindel W, Hesselmann V, Bink A.

Eur Radiol. 2013 Oct;23(10):2868-79. doi: 10.1007/s00330-013-2895-x. Epub 2013 Aug 1.

PMID:
23903995
[PubMed - indexed for MEDLINE]
5.

Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma.

Ellingson BM, Cloughesy TF, Zaw T, Lai A, Nghiemphu PL, Harris R, Lalezari S, Wagle N, Naeini KM, Carrillo J, Liau LM, Pope WB.

Neuro Oncol. 2012 Mar;14(3):333-43. doi: 10.1093/neuonc/nor220. Epub 2012 Jan 22.

PMID:
22270220
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Differentiation of pyogenic brain abscesses from necrotic glioblastomas with use of susceptibility-weighted imaging.

Toh CH, Wei KC, Chang CN, Hsu PW, Wong HF, Ng SH, Castillo M, Lin CP.

AJNR Am J Neuroradiol. 2012 Sep;33(8):1534-8. doi: 10.3174/ajnr.A2986. Epub 2012 Mar 15.

PMID:
22422181
[PubMed - indexed for MEDLINE]
Free Article
7.

Dynamic susceptibility contrast-enhanced perfusion magnetic resonance (MR) imaging combined with contrast-enhanced MR imaging in the follow-up of immunogene-treated glioblastoma multiforme.

Stenberg L, Englund E, Wirestam R, Siesjö P, Salford LG, Larsson EM.

Acta Radiol. 2006 Oct;47(8):852-61.

PMID:
17050367
[PubMed - indexed for MEDLINE]
8.

Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation.

Vidiri A, Pace A, Fabi A, Maschio M, Latagliata GM, Anelli V, Piludu F, Carapella CM, Giovinazzo G, Marzi S.

J Exp Clin Cancer Res. 2012 Apr 11;31:33. doi: 10.1186/1756-9966-31-33.

PMID:
22494770
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery.

Stummer W, Meinel T, Ewelt C, Martus P, Jakobs O, Felsberg J, Reifenberger G.

J Neurooncol. 2012 May;108(1):89-97. doi: 10.1007/s11060-012-0798-3. Epub 2012 Feb 4.

PMID:
22307805
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Comparison of BOLD cerebrovascular reactivity mapping and DSC MR perfusion imaging for prediction of neurovascular uncoupling potential in brain tumors.

Pillai JJ, Zacà D.

Technol Cancer Res Treat. 2012 Aug;11(4):361-74. Epub 2012 Mar 1.

PMID:
22376130
[PubMed - indexed for MEDLINE]
11.

Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T.

Grabner G, Nöbauer I, Elandt K, Kronnerwetter C, Woehrer A, Marosi C, Prayer D, Trattnig S, Preusser M.

Magn Reson Imaging. 2012 Jan;30(1):139-47. doi: 10.1016/j.mri.2011.08.004. Epub 2011 Oct 6.

PMID:
21982163
[PubMed - indexed for MEDLINE]
12.

Fractal analysis of the susceptibility weighted imaging patterns in malignant brain tumors during antiangiogenic treatment: technical report on four cases serially imaged by 7 T magnetic resonance during a period of four weeks.

Di Ieva A, Matula C, Grizzi F, Grabner G, Trattnig S, Tschabitscher M.

World Neurosurg. 2012 May-Jun;77(5-6):785.e11-21. doi: 10.1016/j.wneu.2011.09.006. Epub 2011 Nov 7.

PMID:
22120276
[PubMed - indexed for MEDLINE]
13.

Intraoperative dynamic susceptibility contrast weighted magnetic resonance imaging (iDSC-MRI) - Technical considerations and feasibility.

Ulmer S, Helle M, Jansen O, Mehdorn HM, Nabavi A.

Neuroimage. 2009 Mar 1;45(1):38-43. doi: 10.1016/j.neuroimage.2008.11.021. Epub 2008 Dec 6.

PMID:
19100843
[PubMed - indexed for MEDLINE]
14.

Susceptibility weighted imaging: a new tool in the diagnosis of prostate cancer and detection of prostatic calcification.

Bai Y, Wang MY, Han YH, Dou SW, Lin Q, Guo Y, Li W, Ding DG, Dai JP, Qin W, Shi DP, Tian J, Dai YM.

PLoS One. 2013;8(1):e53237. doi: 10.1371/journal.pone.0053237. Epub 2013 Jan 7.

PMID:
23308170
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Identification of calcification with MRI using susceptibility-weighted imaging: a case study.

Wu Z, Mittal S, Kish K, Yu Y, Hu J, Haacke EM.

J Magn Reson Imaging. 2009 Jan;29(1):177-82. doi: 10.1002/jmri.21617.

PMID:
19097156
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Robust texture features for response monitoring of glioblastoma multiforme on T1-weighted and T2-FLAIR MR images: a preliminary investigation in terms of identification and segmentation.

Assefa D, Keller H, Ménard C, Laperriere N, Ferrari RJ, Yeung I.

Med Phys. 2010 Apr;37(4):1722-36.

PMID:
20443493
[PubMed - indexed for MEDLINE]
17.

Blood volume of gliomas determined by double-echo dynamic perfusion-weighted MR imaging: a preliminary study.

Uematsu H, Maeda M, Sadato N, Matsuda T, Ishimori Y, Koshimoto Y, Kimura H, Yamada H, Kawamura Y, Yonekura Y, Itoh H.

AJNR Am J Neuroradiol. 2001 Nov-Dec;22(10):1915-9.

PMID:
11733325
[PubMed - indexed for MEDLINE]
Free Article
18.

Glioblastomas vs. lymphomas: more diagnostic certainty by using susceptibility-weighted imaging (SWI).

Peters S, Knöß N, Wodarg F, Cnyrim C, Jansen O.

Rofo. 2012 Aug;184(8):713-8. Epub 2012 May 22.

PMID:
22618484
[PubMed - indexed for MEDLINE]
19.

Distinguishing recurrent primary brain tumor from radiation injury: a preliminary study using a susceptibility-weighted MR imaging-guided apparent diffusion coefficient analysis strategy.

Al Sayyari A, Buckley R, McHenery C, Pannek K, Coulthard A, Rose S.

AJNR Am J Neuroradiol. 2010 Jun;31(6):1049-54. doi: 10.3174/ajnr.A2011. Epub 2010 Jan 28.

PMID:
20110377
[PubMed - indexed for MEDLINE]
Free Article
20.

Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival.

Hu LS, Eschbacher JM, Heiserman JE, Dueck AC, Shapiro WR, Liu S, Karis JP, Smith KA, Coons SW, Nakaji P, Spetzler RF, Feuerstein BG, Debbins J, Baxter LC.

Neuro Oncol. 2012 Jul;14(7):919-30. doi: 10.1093/neuonc/nos112. Epub 2012 May 3.

PMID:
22561797
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk